Skip to content

Growth hormone axis

Macimorelin

Also called Macrilen, Ghryvelin

OralEvidence AEvery day
Half-life
4hours
Typical vial
60mg
Research amounts
35–35mg

per administration

Common schedule
Every day
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

Licensed as a medicine in the US and EU.

The human evidence for Macimorelin used the oral route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded175units dialled
Concentration
20mg/mL
Volume per draw
1.75mL
Units to dial
175
Doses per cartridge
1

This is 175 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.

Dial range varies by pen; 1–60 units is the common configuration.

Vial label

Copy this into your label printer.

Published research contexts for Macimorelin describe 3535 mg per administration. Descriptive only, not a recommendation.

About 4 hours; a single oral dose, so the curve here is illustrative.

An oral peptidomimetic secretagogue given as a single 0.5 mg/kg dose (about 35 mg for a 70 kg adult) as a pituitary challenge, licensed in the US and EU; the 60 mg figure shown is the oral packet strength, not a vial, and no injected schedule is established, so no schedule table is shown.

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.02× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
20hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • Garcia JM et al., JCEM 2018;103:3083A single 0.5 mg/kg oral dose used as a growth-hormone secretagogue challenge, validated against the insulin-tolerance challenge for adult growth-hormone deficiency.

Next steps